Showing 38,581 - 38,600 results of 56,807 for search '(( 09 ((0 decrease) OR (a decrease)) ) OR ( 20 ((nn decrease) OR (we decrease)) ))', query time: 0.79s Refine Results
  1. 38581

    Table_1_Prevalence of Inflammatory Pathways Over Immuno-Tolerance in Peripheral Blood Mononuclear Cells of Recent-Onset Type 1 Diabetes.xlsx by Aritania Sousa Santos (11898296)

    Published 2022
    “…The aim of our study was to investigate whether gene expression patterns of PBMC of the highly admixed Brazilian population could add knowledge about T1D pathogenic mechanisms.</p>Methods<p>We assessed global gene expression in PBMC from two groups matched for age, sex and BMI: 20 patients with recent-onset T1D (≤ 6 months from diagnosis, in a time when the autoimmune process is still highly active), testing positive for one or more islet autoantibodies and 20 islet autoantibody-negative healthy controls.…”
  2. 38582

    Table_1_Heterogeneities of Site-Specific N-Glycosylation in HCC Tumors With Low and High AFP Concentrations.xlsx by Ting Zhao (434093)

    Published 2020
    “…By large-scale profiling and quantifying more than 4,700 intact N-glycopeptides from 20 HCC and 20 paired paracancer samples, we identified many commonly altered site-specific N-glycans from HCC tumors regardless of AFP levels, including decreased modifications by oligo-mannose and sialylated bi-antennary glycans, and increased modifications by bisecting glycans. …”
  3. 38583

    Table_7_Heterogeneities of Site-Specific N-Glycosylation in HCC Tumors With Low and High AFP Concentrations.XLSX by Ting Zhao (434093)

    Published 2020
    “…By large-scale profiling and quantifying more than 4,700 intact N-glycopeptides from 20 HCC and 20 paired paracancer samples, we identified many commonly altered site-specific N-glycans from HCC tumors regardless of AFP levels, including decreased modifications by oligo-mannose and sialylated bi-antennary glycans, and increased modifications by bisecting glycans. …”
  4. 38584

    Interplay between fungicides and parasites: Tebuconazole, but not copper, suppresses infection in a <i>Daphnia-Metschnikowia</i> experimental model by Ana P. Cuco (3775534)

    Published 2017
    “…In a follow-up experiment, we tested the effect of a lower range of tebuconazole concentrations (0.00, 6.25, 12.5, 25.0, 50.0 and 100 μg L<sup>-1</sup>) crossed with increasing parasite challenge (2 <i>Daphnia</i> clones × 6 contaminant concentrations × 2 parasite levels × 20 replicates = 480 experimental units). …”
  5. 38585
  6. 38586
  7. 38587

    Data Paper. Data Paper by Matt G. Bradford (401438)

    Published 2016
    “…<h2>File List</h2><div> <p><a href="CSIRO_permanent_plots.zip">CSIRO_permanent_plots.zip</a> (MD5: 05f273b3cf0c52a747bd64f383f8f3a4)</p> <p><a href="CSIRO_Permanent_Rainforest_Plots_of_North_Queensland.html">CSIRO_Permanent_Rainforest_Plots_of_North_Queensland.html</a></p> </div><h2>Description</h2><div> <p>We present repeated stem measurement data from 20 0.5-ha (100 × 50 m) permanent rain forest plots in northern Queensland, Australia from 1971 to 2013. …”
  8. 38588
  9. 38589
  10. 38590
  11. 38591

    Table_2_Heterogeneities of Site-Specific N-Glycosylation in HCC Tumors With Low and High AFP Concentrations.XLSX by Ting Zhao (434093)

    Published 2020
    “…By large-scale profiling and quantifying more than 4,700 intact N-glycopeptides from 20 HCC and 20 paired paracancer samples, we identified many commonly altered site-specific N-glycans from HCC tumors regardless of AFP levels, including decreased modifications by oligo-mannose and sialylated bi-antennary glycans, and increased modifications by bisecting glycans. …”
  12. 38592

    DataSheet_1_4th booster-dose SARS-CoV-2 heterologous and homologous vaccination in rheumatological patients.docx by Maria Jose Gallardo-Nelson (19229509)

    Published 2024
    “…</p>Methods<p>We designed a longitudinal observational study conducted at the rheumatology department of Hospital de Copiapó. …”
  13. 38593
  14. 38594
  15. 38595
  16. 38596
  17. 38597
  18. 38598
  19. 38599
  20. 38600